AVITA Medical (AVITA Medical) Interest Expense : $-1.14 Mil (TTM As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is AVITA Medical Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. AVITA Medical's interest expense for the three months ended in Dec. 2023 was $ -1.12 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.14 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. AVITA Medical's Operating Income for the three months ended in Dec. 2023 was $ -12.27 Mil. AVITA Medical's Interest Expense for the three months ended in Dec. 2023 was $ -1.12 Mil. AVITA Medical did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

AVITA Medical Interest Expense Historical Data

The historical data trend for AVITA Medical's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AVITA Medical Interest Expense Chart

AVITA Medical Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-0.03

-0.02

-1.14

AVITA Medical Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense	Get a 7-Day Free Trial															-0.01	-	-0.01	-0.01	-1.12

AVITA Medical Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.14 Mil.

AVITA Medical (OTCPK:AVHHL) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

AVITA Medical's Interest Expense for the three months ended in Dec. 2023 was $-1.12 Mil. Its Operating Income for the three months ended in Dec. 2023 was $-12.27 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was $41.51 Mil.

AVITA Medical's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

AVITA Medical did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

AVITA Medical (AVITA Medical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » AVITA Medical Inc (OTCPK:AVHHL) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

RCEL:USA 51KB:Germany AVH:Australia

Address

28159 Avenue Stanford, Suite 220, Valencia, Los Angeles, CA, USA, 91355

Website

https://www.avitamedical.com

Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the U.S. with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 U.S. burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the U.S. region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the U.S.